Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Steroids

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.STEROIDS.2006.10.009PMID 17169390PMCID PMC2566956
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Road to Yesterday

  2009cited by this paper
• Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase.

  2007cited by this paper
• Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

  2007cited by this paper
• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  2006cited by this paper
• Three‐dimensional model of the human aromatase enzyme and density functional parameterization of the iron‐containing protoporphyrin IX for a molecular dynamics study of heme‐cysteinato cytochromes

  2006cited by this paper
• 17‐Beta‐Estradiol induces transformation and tumorigenesis in human breast epithelial cells

  2006cited by this paper
• Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention.

  2006cited by this paper
• Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer

  2006cited by this paper
• Estrogen receptors as therapeutic targets in breast cancer.

  2006cited by this paper
• Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

  2006cited by this paper
• The ne w e ngl and j our na l of medicine

  2006cited by this paper
• Adult Weight Change and Risk of Postmenopausal Breast Cancer

  2006cited by this paper
• Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.

  2006cited by this paper
• Clomiphene protects against osteoporosis in the mature ovariectomized rat

  2006cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy.

  2005cited by this paper
• Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy.

  2005influential reference
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

  2005cited by this paper
• Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.

  2005cited by this paper
• Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.

  2005cited by this paper
• Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  2005cited by this paper
• The final catalytic step of cytochrome p450 aromatase: a density functional theory study.

  2005cited by this paper
• Long-term adjuvant tamoxifen study: Clinical update

  2005cited by this paper
• Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.

  2005cited by this paper
• Coregulator function: a key to understanding tissue specificity of selective receptor modulators.

  2004cited by this paper
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

  2004influential reference
• First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group

  2004cited by this paper
• Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

  2004cited by this paper
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

  2004cited by this paper
• Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

  2004cited by this paper
• Selective estrogen receptor modulation: concept and consequences in cancer.

  2004cited by this paper
• First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group.

  2004cited by this paper
• Breast cancer prevention--clinical trials strategies involving aromatase inhibitors.

  2003influential reference
• Tamoxifen: a most unlikely pioneering medicine

  2003cited by this paper
• The estrogen receptor: a model for molecular medicine.

  2003cited by this paper
• Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. Part 1. Receptor Interactions

  2003cited by this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

  2003cited by this paper
• Endocrine therapy of advanced disease: analysis and implications of the existing data.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

  2003cited by this paper
• Apoptotic Action of 17β-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo

  2003cited by this paper
• Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.

  2003cited by this paper
• Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

  2003cited by this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions.

  2003cited by this paper
• Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.

  2003cited by this paper
• American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Adjuvant chemotherapy for breast cancer

  2002cited by this paper
• Aromatase--a brief overview.

  2002cited by this paper
• Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

  2001cited by this paper
• Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.

  2001cited by this paper
• Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis

  2001cited by this paper
• Structural insights into the mode of action of a pure antiestrogen.

  2001cited by this paper
• Selective Estrogen Receptor Modulation : A Personal Perspective 1

  2001cited by this paper
• Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma

  2001cited by this paper
• Selective estrogen receptor modulation: a personal perspective.

  2001cited by this paper
• The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators*

  2001cited by this paper
• Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

  2001cited by this paper
• Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study.

  2001cited by this paper
• High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

  2001cited by this paper
• Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

  2000cited by this paper
• Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

  2000cited by this paper
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

  2000cited by this paper
• Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.

  2000cited by this paper
• Mice help sort out benzodiazepine side-effects

  1999cited by this paper
• Aromatase and its inhibitors.

  1999cited by this paper
• Use of aromatase inhibitors in breast carcinoma.

  1999cited by this paper
• The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.

  1998cited by this paper
• In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture.

  1997cited by this paper
• The minimal effective exemestane dose for endocrine activity in advanced breast cancer.

  1997cited by this paper
• Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.

  1996cited by this paper
• Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation.

  1996cited by this paper
• Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994influential reference
• Randomized trial or the selective aromatase inhibitor formestane (Lentaron®) versus tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer

  1993cited by this paper
• The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.

  1993cited by this paper
• High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients.

  1993cited by this paper
• Tissue-specific promoters regulate aromatase cytochrome P450 expression.

  1993cited by this paper
• Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.

  1992cited by this paper
• Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.

  1992cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• 92099252 Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for nononcological reasons

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women

  1992cited by this paper
• Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1

  1992cited by this paper
• Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.

  1991cited by this paper
• Advances in Comparative and Environmental Physiology

  1991cited by this paper
• Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours.

  1991cited by this paper

• Multifunctional Estrone-Polyoxometalate-F16 Hybrid Conjugate: A Synergistic Targeting Approach against Breast Cancer Cells.

  2025cites this paper
• Identification of genomic features that uniquely impact estrogen receptor alpha binding and its effects on gene expression in endometrial cancer

  2025cites this paper
• Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action

  2025cites this paper
• Letrozol-induzierte Chorioretinopathia centralis serosa

  2025cites this paper
• Molecular, metabolic, and histological subtypes of pancreatic ductal adenocarcinoma and its tumor microenvironment: Insights into tumor heterogeneity and clinical implications.

  2025cites this paper
• Novel immunotherapies for breast cancer: Focus on 2023 findings.

  2024cites this paper
• The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer.

  2024cites this paper
• The elucidation of species-specific receptor pharmacology: a case study using subtype selective para- and meta-carborane estrogen receptor agonists.

  2024cites this paper
• New tamoxifen analogs for breast cancer therapy: synthesis, aromatase inhibition and in silico studies

  2023cites this paper
• Updates in the treatment of HR+HER2- breast cancer

  2023cites this paper
• Effect of variables on exemestane-loaded albumin nanoparticles: statistical optimization and anti-cancer activity in MCF-7 cell lines

  2023cites this paper
• Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches

  2023cites this paper
• The nuclear receptor LRH‐1 discriminates between ligands using distinct allosteric signaling circuits

  2023cites this paper
• The unfolded protein response (UPR) pathway: the unsung hero in breast cancer management

  2022cites this paper
• Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer

  2022cites this paper
• Molecular Docking , ADMET and Pharmacokinetic properties predictions of some di-aryl Pyridinamine derivatives as Estrogen Receptor (Er+) Kinase Inhibitors

  2022cites this paper
• NDR1 increases NOTCH1 signaling activity by impairing Fbw7 mediated NICD degradation to enhance breast cancer stem cell properties

  2022cites this paper
• Mathematical model for the estrogen paradox in breast cancer treatment

  2022cites this paper
• Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer

  2022cites this paper
• Effects of chronic tamoxifen treatment in female rat sexual behaviour

  2022cites this paper
• Aromatase Inhibitors: Development and Current Perspectives

  2022cites this paper
• siRNA-based nanocarriers for targeted drug delivery to control breast cancer

  2022cites this paper
• The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation

  2022cites this paper
• Comparative differential cytotoxicity of clinically used SERMs in human cancer lines of different origin and its predictive molecular docking studies of key target genes involved in cancer progression and treatment responses

  2021cites this paper
• Synthesis and biological evaluation of 17-cyanopyridine derivatives of pregnenolone as potential anti-prostate cancer agents.

  2021cites this paper
• A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses

  2021influential citation
• Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer

  2021cites this paper
• The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer

  2021cites this paper
• Identifying Novel Drug Targets by iDTPnd: A Case Study of Kinase Inhibitors

  2021cites this paper
• PERK, Beyond an Unfolded Protein Response Sensor in Estrogen-Induced Apoptosis in Endocrine-Resistant Breast Cancer

  2021influential citation
• Anastrozole Regulates Fatty Acid Synthase in Breast Cancer

  2021cites this paper
• Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer

  2020influential citation
• QSAR, molecular docking, design, and pharmacokinetic analysis of 2-(4-fluorophenyl) imidazol-5-ones as anti-breast cancer drug compounds against MCF-7 cell line

  2020cites this paper
• Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs

  2020cites this paper
• Tamoxifen induces stem-like phenotypes and multidrug resistance by altering epigenetic regulators in ERα+ breast cancer cells.

  2020cites this paper
• 50th ANNIVERSARY OF THE FIRST CLINICAL TRIAL WITH ICI 46,474 (TAMOXIFEN): THEN WHAT HAPPENED?

  2020influential citation
• Notch Signaling in Breast Cancer: A Role in Drug Resistance

  2020cites this paper
• Formation of Steroid-Type Skeletons: An Ubiquitous Natural Product

  2020cites this paper
• Baicalin inhibits the TGF-β1/p-Smad3 pathway to suppress epithelial-mesenchymal transition-induced metastasis in breast cancer

  2020cites this paper
• Exploration of Binding Interaction of Steroidal Drugs with HMG-CoA Reductase for the Treatment of Breast Cancer Patients who suffer with Cardiovascular Problems: In-silico Studies

  2020cites this paper
• Apigenin Attenuates the Allergic Reactions by Competitively Binding to ER With Estradiol

  2020cites this paper
• The 5,6‐epoxycholesterol metabolic pathway in breast cancer: Emergence of new pharmacological targets

  2020cites this paper
• The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer

  2020cites this paper
• QSAR, Ligand Based Design and Pharmacokinetic Studies of Parviflorons Derivatives as Anti-Breast Cancer Drug Compounds Against MCF-7 Cell Line

  2020cites this paper
• The Effects of Adjuvant Tamoxifen Use on Macula Pigment Epithelium Optical Density, Visual Acuity and Retinal Thickness in Patients with Breast Cancer

  2020cites this paper
• Oestrogen receptors and breast cancer: are we prepared to move forward? A critical review

  2019cites this paper
• Suppression of Nuclear Factor-κB by Glucocorticoid Receptor Blocks Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells

  2019cites this paper
• Mechanisms of cross-resistance to radiotherapy and tamoxifen treatment in breast cancer

  2019influential citation
• The estrogen effect; clinical and histopathological evidence of dichotomous influences in dogs with spontaneous mammary carcinomas

  2019cites this paper
• Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells

  2019cites this paper
• New insights into acquired endocrine resistance of breast cancer

  2019cites this paper
• Estrogen and estrogen receptor signaling promotes allergic immune responses: Effects on immune cells, cytokines, and inflammatory factors involved in allergy.

  2019cites this paper
• Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer

  2019cites this paper
• Targeting cellular cholesterol for anticancer therapy

  2019cites this paper
• ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.

  2019cites this paper
• Hepatic effects of long‐term tamoxifen administration to cycling female rats

  2019cites this paper
• Synthesis and cytotoxicity evaluation of glycosidic derivatives of lawsone against breast cancer cell lines.

  2019cites this paper
• Identifying Novel Targets by using Drug-binding Site Signature: A Case Study of Kinase Inhibitors

  2019cites this paper
• Characterization of a novel androgen membrane receptor in lampreys that may regulate sexual development : androgen binding in lampreys may have implications for steroid ligand and receptor evolution in vertebrates

  2019cites this paper
• Angiogenesis and vascular stability in eicosanoids and cancer

  2018cites this paper
• Chemistry, biochemistry, metabolic fate and mechanism of action of 6-oxo-cholestan-3β,5α-diol (OCDO), a tumor promoter and cholesterol metabolite.

  2018cites this paper
• Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer

  2018cites this paper
• Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer

  2018cites this paper
• Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells

  2018cites this paper
• Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer.

  2018cites this paper
• Precision Medicine in Hormone Receptor-Positive Breast Cancer

  2018cites this paper
• Epigenetic mechanisms regulating epithelial-mesenchymal plasticity in breast cancer

  2018cites this paper
• A role for G-protein coupled estrogen receptor (GPER) in estrogen-induced carcinogenesis: Dysregulated glandular homeostasis, survival and metastasis.

  2018cites this paper
• How PERK kinase conveys stress signals to nuclear factor-κB to mediate estrogen-induced apoptosis in breast cancer cells?

  2018cites this paper
• Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women’s Health

  2018cites this paper
• Metabolite identification of ursolic acid in mouse plasma and urine after oral administration by ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry

  2018cites this paper
• An active and selective molecular mechanism mediating the uptake of sex steroids by prostate cancer cells.

  2018cites this paper
• Steroid receptors in breast cancer

  2018cites this paper
• Design and Synthesis of Novel Chalcone-Phenylpyranone Derivatives as Estrogen Receptor Modulators

  2018cites this paper
• Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells

  2018cites this paper
• Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.

  2017cites this paper
• Analysis of the effect of the over-expression of recptor activator of Nf-kB (RANK) in estrogen receptor-positive breast cancer cells over tumour behaviour in vivo

  2017cites this paper
• TARGETING AUTOPHAGY TO IMPROVE EFFICACY OF CDK4/6 INHIBITION IN BREAST CANCER

  2017cites this paper
• Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents.

  2017cites this paper
• Optimizing Aromatase Expression and Uncovering Novel Allosteric Inhibitors for Breast Cancer Treatment

  2017cites this paper
• Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.

  2017cites this paper
• Stratified medicine: methods for evaluation of predictive biomarkers

  2017cites this paper
• Role of MIR-29B-1 and MIR-29A in endocrine-resistant breast cancer.

  2017cites this paper
• Aromatase Inhibitors in Breast Cancer: The Legacy of Angela M. Hartley Brodie (1934-2017)

  2017cites this paper
• Treatment for the endocrine resistant breast cancer: Current options and future perspectives.

  2017cites this paper
• Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer

  2017cites this paper
• Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.

  2017cites this paper
• Aromatase inhibitors in breast cancer: Signaling pathways involved in exemestane-acquired resistance

  2016influential citation
• Exploring new chemical functionalities to improve aromatase inhibition of steroids.

  2016cites this paper
• Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.

  2016cites this paper
• Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.

  2016cites this paper
• Determination of tamoxifen and its metabolites using micelle to solvent stacking in nonaqueous capillary electrophoresis

  2016cites this paper
• The modulation of estrogen-induced apoptosis as an interpretation of the women’s health initiative trials

  2016cites this paper
• Glycone-rich Soy Isoflavone Extracts Promote Estrogen Receptor Positive Breast Cancer Cell Growth

  2016cites this paper
• Pioneering a Novel Class of Tetrahydroimidazopyridines with Anti-Proliferative Property Study Against Prostate Cancer

  2016cites this paper
• Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and –resistant breast cancer cells

  2016cites this paper
• Treatment for Dementia: Learning from Breakthroughs for Other Conditions.

  2016cites this paper
• Inhibition of macrophage CD 36 expression and cellular oxLDL accumulation by tamoxifen — A PPARγ dependent mechanism

  2016cites this paper
• Inhibition of Macrophage CD36 Expression and Cellular Oxidized Low Density Lipoprotein (oxLDL) Accumulation by Tamoxifen

  2016cites this paper
• Chronic oxidative stress causes estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor alpha in MCF-7 breast cancer cells

  2015cites this paper